atorvastatin / Generic mfg. - LARVOL DELTA

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study. (PubMed, Ther Clin Risk Manag) - P2 | "Hypertriglyceridemia was mostly managed using atorvastatin and simvastatin. The safety data reflected satisfactory tolerability and adverse event management, supporting the involvement of a multidisciplinary disease management team in ovarian cancer care. NCT04376073."

Adverse events • Clinical • Journal • P2 data • Platinum resistant • Cardiovascular • Dermatology • Dyslipidemia • Hematological Disorders • Hypertension • Hypertriglyceridemia • Leukopenia • Neutropenia • Oncology • Ovarian Cancer • Solid Tumor • Thrombocytopenia

Potency Matters: The Role of Statin Intensity in Modulating Risk for Age-Related Macular Degeneration. (PubMed, Am J Ophthalmol) - "In this study of patients with type 2 diabetes and dyslipidemia, medium- and high-intensity, but not low-intensity, statin therapies were associated with a reduced risk of AMD. Further research is needed to confirm these findings and elucidate the underlying mechanisms."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Macular Degeneration • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

Unlocking the inflammatory 'code' in multivessel coronary disease: pathological network mediated by the PCSK9-NLRP3 axis and a novel microcirculatory dysfunction prediction model (ESC-WCC 2025) - "In MVD patients, 36 received atorvastatin+probucol (intervention) and 43 received atorvastatin alone (control)...Probucol reduces NLRP3 and mitigates PCSK9 elevation, suggesting anti-inflammatory effects via inflammasome modulation. Combining PCSK9 inhibitors with anti-inflammatory agents may optimize MVD therapy."

Atherosclerosis • Cardiovascular • IL18 • IL1B • MVD • NLRP3 • PCSK9 • TLR4

Achievement of LDL-C targets after acute myocardial infarction in a public healthcare center in Brazil (ESC-WCC 2025) - "At the study center, within the framework of the Brazilian Unified Health System (SUS), only simvastatin and atorvastatin were available for prescription. At this public tertiary center in Brazil, most patients with a history of AMI received high-intensity statin therapy. Despite an increased number of patients achieving either the < 50 mg/dl goal or at least 50% reduction, most patients remained off the ideal target and under increased risk of recurrent events. Poor adherence and low accessibility to novel and potent lipid-lowering therapies are probably important players in this scenario."

Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hypertension • Myocardial Infarction

Bempedoic acid in clinical practice. (ESC-WCC 2025) - "The majority had coronary artery disease (91.5%) and preserved left ventricular function (72%).The most commonly used statin was rosuvastatin (60.7%), followed by atorvastatin (33.9%)...Additionally, 7.3% were taking icosapent ethyl...ConclusionsBempedoic acid is a valuable tool for lowering LDL cholesterol and preventing cardiovascular events, especially in patients who cannot tolerate statins or do not reach target levels. Its efficacy and safety, achieving LDL reductions of around 18% demonstrated both in clinical trials and increasingly in clinical practice, as well as the possibility of taking it in a single pill with ezetimibe, position it as an important therapeutic option in the current management of dyslipidaemia."

Clinical • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hypertension • CRP

Early high intensity lipid-lowering therapy in STEMI patients with primary PCI improves myocardial perfusion (ESC-WCC 2025) - "Pts in group 1 with moderate-Intensity LLT (n=50) received either atorvastatin (A) 40 mg or a combination of A 10 mg and ezetimibe (E) 10 mg. Conclusion. The study revealed that lipid metabolism disorders cannot serve as markers of MBG but the high-intensity LLT significantly improves the quality of myocardial tissue perfusion."

Clinical • Cardiovascular • Dyslipidemia • Myocardial Infarction • CRP

High-intensity lipid-lowering therapy accelerates early plaque regression: a FLOWPROMOTE sub study. (ESC-WCC 2025) - "Patients were randomized 1:1 to either usual care LLT (UC-LLT, 40 mg atorvastatin daily) or intensive care LLT (IC-LLT, 40 mg rosuvastatin plus 10 mg ezetimibe daily) for 18 months with repeat CCTA scans at 9- and 18-months follow-up. Intensive versus usual care LLT is associated with more profound and accelerated plaque regression during the first 9 months of treatment. Large-scale prospective studies with clinical event-driven endpoints are needed to determine the prognostic significance of early plaque modification."

Atherosclerosis • Cardiovascular • Coronary Artery Disease

Unmet needs of LDL C lowering in ACS patients when using only high intensity statins puts at setback (ESC-WCC 2025) - "About 86.4% patients were on atorvastatin...CONCLUSION Our study have demonstrated that more than 50% of patients fail to achieve their LDL-C goal on high intensity stating monotherapy. Therefore, early combination of oral lipid lowering therapy may be preferred than statin monotherapy for rapid achievement of LDL-C goals in selected patients (those with high baseline LDL-C) in ACS."

Clinical • Cardiovascular

Physician perspectives on lipoprotein (a) testing and treatment for secondary prevention of cardiovascular disease - results from 7 countries across 6 WHO regions from the INTERASPIRE study (ESC-WCC 2025) - "58.4% chose atorvastatin and 40.4% rosuvastatin as their first choice of statin... Most physicians use European or American guidelines on management of dyslipidaemias. A large majority try to achieve a lower LDL-C target by using high intensity statins, especially the cardiologists. There is marked heterogeneity in access to Lp(a) testing for physicians and where it is available less than half measure it routinely in patients with coronary disease."

Cardiovascular • Coronary Artery Disease • Dyslipidemia

Triple oral lipid-lowering treatment pathway and associated outcomes in high- and very high-cv risk patients: a simulation using the SANTORINI study cohort (ESC-WCC 2025) - "The potential clinical utility of combining the three available oral medications - statins, ezetimibe, and bempedoic acid (BA) - has not been characterized in larger real-world populations...A Monte Carlo simulation (10,000 iterations) modelled a three-step LLT intensification pathway: statin optimization, consisting of initiation (atorvastatin 40mg) or up-titration (to atorvastatin 40mg, if not already on higher or equivalent statin intensity or on combination therapy with ezetimibe), ezetimibe addition, and BA addition if LDL-C remained above goal after each optimization step...The predicted relative risk reduction in major CV events (as defined by the CTTC) in the simulation cohort was 11.8% after statin optimization, 18.7% after ezetimibe addition, and 22.6% after BA addition, equating to predicted absolute risk reductions of 3.7%, 5.7%, and 6.8%, respectively, from a baseline 10-year risk of 29.8%. Conclusions Real-world data from the large contemporary SANTORINI..."

Clinical • Cardiovascular • Dyslipidemia

Underuse of statins and antiplatelet therapy in high-risk cardiovascular patients: sex-based differences (ESC-WCC 2025) - "High-intensity statin therapy was defined as atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily...Overall, 76.5% of patients received either antiplatelet or anticoagulant therapy, while 67.3% were on statins, 6.3% on ezetimibe, and 4.1% on fibrates...The observed sex-based differences suggest that women may receive less aggressive preventive strategies, highlighting the need for targeted interventions. Additionally, patient awareness of statin benefits appears to influence adherence, underscoring the importance of education in optimizing long-term cardiovascular prevention."

Clinical • Atherosclerosis • Cardiovascular

Eighteen-year trends in cardiovascular risk and mortality in patients with acute coronary syndrome without ST-segment elevation (ESC-WCC 2025) - "We observed a transition to more potent anti-thrombotic agents (from clopidogrel to ticagrelor and prasugrel) and high-intensity statins (from simvastatin to atorvastatin and rosuvastatin). These real-world data demonstrate a substantial decline in the 2-year risk of recurrent myocardial infarction and cardiovascular death following a first-time NSTEMI/UAP event between 2004 and 2021. The improvements in cardiovascular risk coincided with 1) changes in the diagnostic evaluation of obstructive CAD, 2) a reduction in coronary revascularization – in particular a 50% decline in coronary bypass surgery, and 3) optimized medical therapy."

Clinical • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Infarction

The reduction of clot lysis time on statins is associated with lipid plaque parameters in optical coherence tomography in acute myocardial infarction (ESC-WCC 2025) - "In all patients high-dose statin therapy (rosuvastatin 20-40 mg/day or atorvastatin 40-80 mg/day) was initiated within 24 hours from admission... As has been shown for the first time the statin-induced reduction of clot lysis time was independently associated with lipid plaque parameters assessed in the acute AMI phase in OCT. The detailed OCT analysis may serve for prediction of lipid-lowering and fibrinolytic response on high-dose statins in AMI."

Atherosclerosis • Cardiovascular • Dyslipidemia • Myocardial Infarction

Impact of atorvastatin on serum oestradiol and estrone concentrations in postmenopausal women with chronic coronary artery disease: a randomized trial. (ESC-WCC 2025) - "Atorvastatin reduced serum estrone concentrations, which may partly explain the lower efficacy of statins in postmenopausal women. Future studies with more participants and longer follow-ups are needed to confirm these findings and clarify the mechanisms involved."

Clinical • Atherosclerosis • Cardiovascular • Coronary Artery Disease • CRP

Atorvastatin and left ventricular global longitudinal strain during anthracycline-based chemotherapy (ESC-WCC 2025) - "Conclusion Atorvastatin did not significantly reduce the risk of a ≥15% relative decline in LV GLS in lymphoma patients undergoing anthracycline-based chemotherapy. An abnormal follow-up GLS value at 12 months was associated with worse HF and cardiac hospitalization outcomes at 24 months."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Intensified hypolipidaemic therapy with inclisiran for atherosclerotic plaque stabilization (ESC-WCC 2025) - "Study participants were on high-dose statin (atorvastatin 40/80 mg or rosuvastatin 20/40 mg) and optional ezetimibe therapy for 4-6 week run-in period. Intensive pharmacological lipid lowering contributes to plaque stabilization evaluated by NIRS, LDL-C target achievement being important for lipid content reduction. Inclisiran is an effective bailout option for those not fully responsive to statin/ezetimibe."

Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia

Upgrading the STEMI emergency kit: a meta-analysis of randomized controlled trials (ESC-WCC 2025) - "Loading strategies of 40-80 mg of atorvastatin or 20-40 mg of rosuvastatin were admitted... Our results indicate that high-dose statin loading prior to PCI in STEMI patients is associated with a significant improvement in post-PCI TIMI flow 3 and a reduction in the incidence of 30-day MACE. These findings support the clinical benefit of implementing high-dose statin loading in the acute management of STEMI. Therefore, we consider that further research is warranted with larger-scale RCTs."

Retrospective data • Cardiovascular • Myocardial Infarction

Impact of low-intensity versus moderate-high-intensity lipid-lowering treatment on outcomes in AMI patients aged 80 and older: a retrospective cohort study (ESC-WCC 2025) - "Moderate and high intensity LLT was defined as 10 mg or more atorvastatin, 20 mg or more rosuvastatin, PCSK9 inhibitor, or any combination of ezetimibe, PCSK9 inhibitor and statins. Moderate and high intensity LLT were associated with a significant reduction in all-cause and cardiovascular mortality at 3 years among MI patients aged over 80 years, compared to low intensity LLT. These results were predicated on the foundation of effective LLT in our analysis, which provided valuable guidance for clinicians when prescribing lipid-lowering therapies for elderly myocardial infarction patients."

Retrospective data • Cardiovascular • Myocardial Infarction

The association between the response of lipid-lowering agents and monogenic variants of familiar hypercholesteremia in Taiwan (ESC-WCC 2025) - "Moreover, FH carriers exhibited a lower rate of achieving the treatment goal of an LDL-C level less than 70 mg/dL (18.2% in FH carriers versus 66.3% in non-FH carriers on atorvastatin, p< 0.001; and 47.8% in non-FH carriers on rosuvastatin, p= 0.001)...Conclusions CAD patients who are carriers of FH variants exhibit a diminished response to lipid-lowering therapies. Higher-intensity lipid-lowering therapy is recommended for FH patients to achieve more favorable therapeutic outcomes."

Cardiovascular • Coronary Artery Disease • Dyslipidemia • APOB

Effect of coronary calcium-informed statin therapy on peri-coronary adipose tissue attenuation in intermediate-risk patients: post-hoc analysis of the CAUGHT-CAD randomised-controlled trial (ESC-WCC 2025) - "Participants were randomised to a coronary artery calcium score (CACS) informed prevention arm (atorvastatin 40mg/daily and nurse-led tailored lifestyle intervention), and a usual care arm (general lifestyle advice)... Despite reductions in lipid levels, risk prediction scores and lesser plaque progression, a CACS-informed strategy of statin therapy with tailored lifestyle intervention did not have any effect on change in PCAT attenuation."

Clinical • Retrospective data • Cardiovascular • Coronary Artery Disease • Dyslipidemia

Atorvastatin active metabolite inhibits oxidation of Lp(a), small dense LDL and triglyceride-rich lipoproteins compared to other statins through a free radical scavenging mechanism (ESC-WCC 2025) - "Purpose: We compared the effects of 2-o-hydroxy atorvastatin (atorva(m)) to other statins in active form – namely pitavastatin, rosuvastatin, pravastatin, and simvastatin – on rates of lipoprotein oxidation in plasma samples enriched with Lp(a), sdLDL and VLDL. Atorva(m) inhibited oxidation of Lp(a) enriched plasma in a time- and dose-dependent fashion compared to other widely used statins due to free radical scavenging properties. The antioxidant activity extended to other atherogenic ApoB particles including sdLDL. The potent antioxidant actions of atorvastatin active metabolites may reduce the atherogenicity of Lp(a) in patients with elevated Lp(a) concentrations independent of changes in lipid levels."

Cardiovascular • APOB

The SLCO1B1 c.521 T > C variant is not associated with muscular symptoms or PCSK9-inhibitor prescription in patients with severe hypercholesterolemia (ESC-WCC 2025) - "The SLCO1B1 c.521 T > C variant reduces its activity and has been associated with increased risk for statin associated muscle symptoms (SAMS) in particular in patients treated with simvastatin and may thereby increase the risk of statin discontinuation...In addition, statin usage was similar in both groups (69.0 % vs 72.3 %; p=0.63) with no differences in type of statin: rosuvastatin (51.1 % vs. 51.8 %) and atorvastatin (16.9% vs. 20.5 %; p=0.78)...In addition, the presence of the SLCO1B1 c.521 T > C variant was not associated with decreased prescription of statins or increased prescription of PCSK9i. These results question the clinical relevance of determining the SLCO1B1 c.521 T > C polymorphism in the era of modern statin therapy."

Clinical • Cardiovascular • Dyslipidemia

Statin adherence in primary care among patients with hypertension with and without other cardiometabolic diseases (ESC-WCC 2025) - "The most dispensed statins were simvastatin (58%) and atorvastatin (41%). Adherence varied across PHCCs, indicating variability in care. Clinicians might consider these associations when initiating statin therapy."

Adherence • Clinical • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypertension

LDL-C targets after administration of the combination of bempedoic acid and ezetimibe in patients with acute coronary syndrome: an observational study with simulation analysis. (ESC-WCC 2025) - "At hospital discharge, all patients were prescribed high-intensity statins (atorvastatin 80 mg in 54.8% and rosuvastatin 40 mg in 45.2%)...The simulation analysis showed that after the administration of a fixed-dose combination of bempedoic acid and ezetimibe, the mean LDL-C could be reduced to 41.8 (14.8) mg/dL, with 79.5% of patients reaching the lipid goal. Despite receiving high-intensity statins, a considerable proportion of patients did not reach the LDL-C goal recommended by current guidelines. The systematic and early use of the combination of bempedoic acid and ezetimibe could enable a greater number of patients, following an ACS, to achieve LDL-C targets at 6 weeks."

Clinical • Observational data • Acute Coronary Syndrome • Cardiovascular

Empowering patient choice: a randomized trial on statin adherence and side effect reduction (PASTA Trial) [WITHDRAWN] (ESC-WCC 2025) - "Purpose This study aimed to compare six-month adherence to atorvastatin therapy between patients who received routine reassurance and those offered a trial of red yeast rice extract before transitioning to atorvastatin...This approach may enhance statin compliance in primary prevention, particularly for patients initially reluctant to start therapy. Further research is needed to confirm these findings."

Adherence • Adverse events • Clinical • Cardiovascular